Robert Iannone insider trades: Jazz Pharmaceuticals (JAZZ) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | JAZZ | ↓ Sell | 76,921 | $249.70 | $19.2M | Direct | Aug 31, 2026 (4d) |
| Nov 17, 2025 | JAZZ | ↓ Sell | 7,159 | $168.26 | $1.2M | Direct | Nov 19, 2025 (2d) |
| Mar 10, 2025 | JAZZ | ↓ Sell | 2,403 | $138.41 | $333K | Direct | Mar 12, 2025 (2d) |
| Mar 7, 2025 | JAZZ | ↓ Sell | 7,080 | $138.60 | $981K | Direct | Mar 7, 2025 (0d) |
| Dec 9, 2022 | JAZZ | ↓ Sell | 1,844 | $151.54 | $279K | Direct | Dec 13, 2022 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other JAZZ insiders
Open-market trades in the last 12 months
About Robert Iannone's insider trades
Robert Iannone is EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals (JAZZ). Since Dec 9, 2022, Robert has reported no open-market purchases and 5 sales worth $22.0M on SEC Form 4. In the last 12 months: 2 sales ($20.4M).
Their filings also include grants and awards (23 filings), shares withheld for taxes (12 filings), shares returned to the company (3 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JAZZ insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.